Skip to main content

Management of Medical Emergency-Anaphylaxis!

 MEDICAL EMERGENCY- ANAPHYLAXIS

Definition:

"Anaphylaxis is a systemic response to exposure to an allergen caused by rapid, IgE-mediatd release of histamine and other mediators from tissue mast cells and circulating basophils".

Symptoms:

  • Symptoms usually occur within a few seconds or minutes of exposure but can be delayed or recur many hours after apparent resolution (exposure).

Causes:

  1. Upper airway obstruction
  2. Cardiovascular collapse

are the most common causes of death in anaphylaxis.

Treatment:

The treatment of anaphylaxis is directed towards its three Major Presentations:

  1. Skin Manifestations: Angioedema, Urticaria
  2. Respiratory distress: Wheezing, Stridor, Dyspnea from laryngeal edema, laryngospasm and bronchospasm
  3. Hypotension

All specific treatment measures should be accompanied by basic resuscitative measures including clear airway, supplemented oxygen and IV access.

General Therapy and Skin Manifestations:

1. Epinephrine HCl, IM or SC, 0.3-0.5mg; may repeat q(every) 10-15 minutes. In children, 10microgram/kg up to 500 microgram/dose.

2. Diphenhydramine, IV or IM, 1-2mg/kg (up to 50mg) over 5-10 minutes.

3. Cimetidine, IV, 300mg over 5 minutes for urticaria or if hypotension does not respond to fluid replacement and pressors. In children, 3-5mg/kg IV.

4. Although controversial, corticosteroids such as Hydrocortisone phosphate or Succinate, IV, 200mg or Methylprednisolone, IV, 1-2mg/kg might reduce the risk of recurrent or prolonged anaphylaxis.

Respiratory Distress:

1. Assure adequate oxygenation with supplemented oxygen by mask titrated to an oxygen saturation above 90%.

2. In addition to the general therapy described above, add Albuterol, by nebulization, 2.5-5mg q 20 minutes. In children, 0.15mg/kg by nebulization q 20 minutes.

3. If response is inadequate after 3-4 doses of intermittent Albuterol, consider Albuterol, by continuous nebulization, 10-15mg/hr. In children, 0.5mg/kg/hr. by continuous nebulization.

Hypotension:

1. If response to the general therapy described above is inadequate, give NS or Lactated Ringers Injection, IV, 500-1000mL initially and continue at high flow rate. In children, 10-20mL/kg IV initially.

2. Epinephrine HCl, IV continuous infusion, 1 microgram/min, up to 10 microgram/min.

3. Dopamine HCl, IV, 2-5 microgram/kg/minute, titrate to desired effect.

4. Patients taking Beta-adrenergic Blockers may not respond adequately to epinephrine and Fluid replacement and can be adversely affected by unopposed Alpha-adrenergic stimulation from Epinephrine. Glucagon, IV, 5-10mg followed by 1-5mg/hr. by continuous infusion can increase myocardial contractility independent of Beta receptors.


Information notes:

*Salbutamol is also known as Albuterol (Beta2 adrenergic agonist).

Lactated Ringers solution also known as Sodium lactate solution. For replacing fluids and electrolytres.

Glucagon is a peptide hormone produced by Alpha cells of pancreas. It causes increased glucose and fatty acids in blood stream. Also considered as a Catabolic hormone



Comments

Popular posts from this blog

PNEUMONIA- Its Etiology, Pathophysiology, Classification and Severity Assessment Method!

 PNEUMONIA Definition: "Pneumonia is an infection of pulmonary parenchyma". (Harrison)                                                    OR "Pneumonia is defined as an acute respiratory illness associated with recently developed radiological pulmonary shadowing which may be segmental, lobar or multilobar". (Davidson) Etiology: Microorganisms gain excess to the lower respiratory tract in several ways: Aspiration from the oropharynx (most common). Inhalation of contaminated droplets. Hematogenous spread. Contiguous extension. Pathophysiology of Pneumonia: Pneumonia results from proliferation of microbial pathogens at the alveolar level and the hosts response to these microorganisms.  Defensive Mechanisms against Pneumonia: The defensive mechanism against pneumonia involve: Branching architecture of tracheobronchial tree. Muco-ciliary clearance. Local...

Drug-Induced Ototoxicity!

 DRUG-INDUCED OTOTOXICITY What is drug Induced Ototoxicity? Drug-Induced ototoxicity can affect hearing (auditory or cochlear function0, balance (vestibular function) depending on the drug. Drugs of almost every class have been reported to produce tinnitus (sounds in ear), as have placebos. The following agents are associated with measurable changes in hearing or vestibular defect when administered systemically. 1. AMINOGLYCOSIDES: Aminoglycosides antibiotics can cause cochlear or vestibular toxicities. Cochlear toxicity: occurs as progressive hear loss, starting with highest tones and advancing to lower tones. Thus, considerable damage can occur before the patient recognizes it. S ymptoms of Vestibular damage : include;  Dizziness Vertigo Ataxia Both forms of ototoxicity are bilateral and potentially reversible, but permanent damage is common and can progress even after discontinuation of aminoglycosides. Clinically detectable ototoxicity in as many as 5% patients. Most amin...

Diabetes Mellitus: Types!

TYPES OF DIABETES MELLITUS 1. TYPE1 DM Type 1 DM is usually diagnosed before age 30 years, but it can develop at any age. T1DM is an autoimmune disease in which insulin producing B-cells are destroyed. The presence of Human Leucocyte Antigens (HLAs ) is associated with the development of T1DM. In addition, these individuals often develop Islet cell antibodies , Insulin Autoantibodies or Glutamic Acid decarboxylase autoantibodies . At the time of development of diagnosis of T1DM, it is usually believed that most of the patients have 80-90%loss of beta cells. The remaining beta cells function at the diagnosis creates a " HONEYMOON PERIOD" during which the blood glucose levels are easier to control, and smaller amounts of insulin are required. after this, the remaining beta cells function is completely lost, and the patients become completely deficient of insulin and hence require exogenous insulin.  2. TYPE1.5 DM:  Also referred as Latent autoimmune diabetes in Adults (LAD) ...